Xie Xuelu, Lian Shan, Yang Wenyong, He Sheng, He Jingqiu, Wang Yuke, Zeng Yan, Lu Fang, Jiang Jingwen
Department of Ophthalmology, West China Hospital and West China School of Public Health and West China Fourth Hospital, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Tianfu Jincheng Laboratory, Chengdu, 610041, China.
Department of Neurosurgery, Medical Research Center, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated to Chongqing Medical University, The Third People's Hospital of Chengdu, Chengdu, 610014, China.
J Pharm Anal. 2025 May;15(5):101145. doi: 10.1016/j.jpha.2024.101145. Epub 2024 Nov 16.
Age-related macular degeneration (AMD) is a disease that affects the vision of elderly individuals worldwide. Although current therapeutics have shown effectiveness against AMD, some patients may remain unresponsive and continue to experience disease progression. Therefore, in-depth knowledge of the mechanism underlying AMD pathogenesis is urgently required to identify potential drug targets for AMD treatment. Recently, studies have suggested that dysfunction of mitochondria can lead to the aggregation of reactive oxygen species (ROS) and activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) innate immunity pathways, ultimately resulting in sterile inflammation and cell death in various cells, such as cardiomyocytes and macrophages. Therefore, combining strategies targeting mitochondrial dysfunction and inflammatory mediators may hold great potential in facilitating AMD management. Notably, emerging evidence indicates that natural products targeting mitochondrial quality control (MQC) and the cGAS/STING innate immunity pathways exhibit promise in treating AMD. Here, we summarize phytochemicals that could directly or indirectly influence the MQC and the cGAS/STING innate immunity pathways, as well as their interconnected mediators, which have the potential to mitigate oxidative stress and suppress excessive inflammatory responses, thereby hoping to offer new insights into therapeutic interventions for AMD treatment.
年龄相关性黄斑变性(AMD)是一种影响全球老年人视力的疾病。尽管目前的治疗方法已显示出对AMD的有效性,但一些患者可能仍然无反应,并继续经历疾病进展。因此,迫切需要深入了解AMD发病机制背后的机制,以确定AMD治疗的潜在药物靶点。最近,研究表明线粒体功能障碍可导致活性氧(ROS)聚集和环磷酸鸟苷-腺苷酸合成酶(cGAS)/干扰素基因刺激因子(STING)先天免疫途径的激活,最终导致各种细胞(如心肌细胞和巨噬细胞)发生无菌性炎症和细胞死亡。因此,结合针对线粒体功能障碍和炎症介质的策略可能在促进AMD管理方面具有巨大潜力。值得注意的是,新出现的证据表明,针对线粒体质量控制(MQC)和cGAS/STING先天免疫途径的天然产物在治疗AMD方面显示出前景。在这里,我们总结了可能直接或间接影响MQC和cGAS/STING先天免疫途径及其相互关联介质的植物化学物质,这些介质有可能减轻氧化应激并抑制过度的炎症反应,从而希望为AMD治疗的治疗干预提供新的见解。